---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-006396"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:35:03.267364+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024

## Summary
- Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.
- Net loss of $3.1M for Q1 2024; R&D expenses rose to $1.6M on STAR-1 trial costs.
- STAR-1 Phase 3 acne trial enrollment on track for completion by end of 2024; topline data expected Q1 2025.
- Partnership discussions ongoing for DMT410 topical botulinum toxin; Japanese patent issued for hyperhidrosis.
- Company expects current cash to fund operations only into Q3 2024.

## SEC filing metadata
- accession: 0001654954-24-006396
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/0001654954-24-006396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-006396
- JSON: https://secwatch.observer/filing/0001654954-24-006396.json
- Plain text: https://secwatch.observer/filing/0001654954-24-006396.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million of net loss.
  - Period: first quarter ended March 31, 2024
  - Net income: $3.1 million of net loss
  - Result: reported results
  source text: The decrease in cash and cash equivalents resulted from $3.1 million of net loss for the quarter ended March 31, 2024, and $0.2 million of decreased accrued liabilities, offset by $0.6 million in stock-based compensation expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495424006396/0001654954-24-006396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.